Price and Review,Helix BioPharma is developing a proprietary platform of bio-conjugates

The field of therapeutic development is constantly evolving, seeking innovative ways to address complex diseases and previously "undruggable" targets. Among the most promising advancements is the development of helicon peptides, a new class of therapeutics engineered to address targets with unprecedented precision. These alpha-helically locked peptides represent a significant leap forward in peptide drug discovery, offering the potential to revolutionize medicine.

At the core of this innovation is the Helicon™ platform, a sophisticated system designed to engineer precisely tuned, stabilized helical peptide therapeutics. This platform leverages proprietary α-helix conformational hyperstabilization chemistry and advanced technologies like ML-driven Helicon peptide drug discovery platforms. The result is a class of molecules known as helicon peptides, which are essentially conformationally hyperstabilized α-helical peptides (Helicons). These peptides are characterized by their stable helical structures, often achieved through methods like stapled peptides and compositions thereof, which involve chemically cross-linking the helix to enhance its stability.

The unique structural properties of helicon peptides allow them to bind to intracellular targets with remarkable specificity. Unlike traditional small molecules or antibodies, helicon peptides can access binding sites on proteins that were previously considered inaccessible. This ability to target intracellular proteins opens up vast therapeutic possibilities. For instance, ERG-degrading Helicon peptides have shown potent and durable reduction of ERG protein levels, a protein that is overexpressed in a significant percentage of prostate cancers (40-50%). This offers a novel therapeutic approach for these challenging malignancies.

Pioneering companies like FogPharma (now rebranded as Parabilis Medicines) have been at the forefront of helicon peptide development. Their FogPharma's Helicon peptide drug discovery engine has been instrumental in creating a pipeline of innovative therapies. A prime example is FOG-001 (zolucatetide), an intracellular TCF-blocking β-catenin inhibitor. This Helicon-based therapy emerged from their platform and is undergoing clinical development. The success and potential of this approach have attracted substantial investment, with Parabilis Medicines securing significant funding to continue their work.

The scientific community is actively exploring the diverse applications of helicon peptides. Research has demonstrated methods for the de novo discovery of Helicons for protein targets without prior knowledge of their α-helix binding properties. Furthermore, the development of α-helically constrained (Helicon) polypeptides that cooperatively induce interactions between proteins is paving the way for novel drug mechanisms. The ability of these peptides to be cellularly permeable is a critical factor, allowing them to reach their intracellular targets effectively.

Beyond direct therapeutic intervention, helicon peptides are also being explored for other applications. For example, Helicon-enabled alpha radioligand therapies are being developed, aiming to deliver precisely tuned radioligands for cancer treatment. The underlying technology is also being adapted for other therapeutic modalities, such as elastin-like polypeptide (ELP) based targeting biopolymers, which can be engineered for targeted drug delivery.

The therapeutic potential of peptides in general is well-established. As of 2022, over 60 peptide drugs have been approved by regulatory bodies like the FDA and EMA for treating a range of diseases, including diabetes, infections, and cancer. Helicon peptides represent the next generation in this therapeutic class, building upon the established success of peptide therapeutics and expanding their reach to previously intractable targets. The ongoing research and development in this area, including the exploration of novel high affinity bivalent helically constrained peptide designs, suggest a bright future for helicon polypeptides in transforming patient care. The ability to engineer precisely tuned, stabilized helical peptide therapeutics is not just an advancement; it's a paradigm shift in how we approach disease at the molecular level.